Zevra Therapeutics reported earnings of $ 0.26 per ZVRA share on Nov 3, 2026, beating analysts' expectations by
| Report Date | Nov 3, 2026 |
|---|---|
| Forecasted EPS | $ 0.1576 |
| Earnings Per Share (Surprise) | $ 0.26 (+$ 0.1024) |
| Last Year's EPS | $ 0.3375 |
| EPS YoY Change |
Out of the last 52 earnings reporting periods, Zevra Therapeutics beat analysts’ expectations 19 times and fell short of expectations 25 time(s). Zevra Therapeutics reported earnings per share of $ 0.26 in the last report surpassing an estimated EPS of $ 0.1576 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 3, 2026 | $ 0.1576 | $ 0.26 | -$ 0.01 | |
| Aug 5, 2026 | $ 0.11 | $ 0.14 | $ 1.21 | |
| May 6, 2026 | $ 0.06 | $ 0.60 | -$ 0.06 | |
| Mar 9, 2026 | $ 0.05040 | $ 0.21 | -$ 0.67 | |
| Nov 5, 2025 | -$ 0.02 | -$ 0.01 | -$ 0.69 | |
| Aug 12, 2025 | $ 2.19 | $ 1.21 | -$ 0.48 | |
| May 13, 2025 | -$ 0.21 | -$ 0.06 | -$ 0.40 | |
| Mar 11, 2025 | -$ 0.39 | -$ 0.67 | -$ 0.40 | |
| Nov 12, 2024 | -$ 0.44 | -$ 0.69 | -$ 0.40 | |
| Aug 13, 2024 | -$ 0.47 | -$ 0.48 | -$ 0.15 | |
| May 8, 2024 | -$ 0.49 | -$ 0.40 | -$ 0.34 | |
| Mar 28, 2024 | -$ 0.20 | -$ 0.40 | -$ 0.26 | |
| Nov 7, 2023 | -$ 0.29 | -$ 0.40 | -$ 0.19 | |
| Aug 14, 2023 | -$ 0.39 | -$ 0.15 | -$ 0.70 | |
| May 15, 2023 | -$ 0.26 | -$ 0.34 | -$ 0.05 | |
| Mar 7, 2023 | -$ 0.21 | -$ 0.26 | -$ 0.08 | |
| Nov 9, 2022 | -$ 0.13 | -$ 0.19 | -$ 0.05 | |
| Aug 11, 2022 | -$ 0.12 | -$ 0.70 | $ 0.21 | |
| May 12, 2022 | -$ 0.05 | -$ 0.05 | -$ 0.54 | |
| Mar 30, 2022 | -$ 0.07 | -$ 0.08 | -$ 1.07 |
Zevra Therapeutics’s stock was trading at $ 10.10 on Nov 2, 2026 a day before the last earnings report was released.Following the release of the earnings report, ZVRA’s price increased to $ 11.17 on Nov 4, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 3, 2026 | $ 0.26 | $ 10.10 | $ 11.17 | |
| Aug 5, 2026 | $ 0.14 | $ 10.52 | $ 11.88 | |
| May 6, 2026 | $ 0.60 | $ 10.61 | $ 11.00 | |
| Mar 9, 2026 | $ 0.21 | $ 8.98 | $ 11.06 | |
| Nov 5, 2025 | -$ 0.01 | $ 9.79 | $ 9.09 | |
| Aug 12, 2025 | $ 1.21 | $ 11.70 | $ 9.43 | |
| May 13, 2025 | -$ 0.06 | $ 7.75 | $ 8.14 | |
| Mar 11, 2025 | -$ 0.67 | $ 8.00 | $ 7.92 | |
| Nov 12, 2024 | -$ 0.69 | $ 8.96 | $ 8.66 | |
| Aug 13, 2024 | -$ 0.48 | $ 6.81 | $ 6.99 | |
| May 8, 2024 | -$ 0.40 | $ 5.18 | $ 5.03 | |
| Mar 28, 2024 | -$ 0.40 | $ 5.94 | $ 5.16 | |
| Nov 7, 2023 | -$ 0.40 | $ 4.56 | $ 4.44 | |
| Aug 14, 2023 | -$ 0.15 | $ 5.20 | $ 5.23 | |
| May 15, 2023 | -$ 0.34 | $ 4.23 | $ 4.67 | |
| Mar 7, 2023 | -$ 0.26 | $ 5.35 | $ 4.13 | |
| Nov 9, 2022 | -$ 0.19 | $ 5.64 | $ 4.61 | |
| Aug 11, 2022 | -$ 0.70 | $ 6.46 | $ 6.11 | |
| May 12, 2022 | -$ 0.05 | $ 4.02 | $ 4.10 | |
| Mar 30, 2022 | -$ 0.08 | $ 5.28 | $ 5.03 |
Zevra Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Zevra Therapeutics beat analysts’ expectations during the last earnings period by
